| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Roncaglia, Eleonora |
| dc.contributor.author | GAFFO, Enrico |
| dc.contributor.author | Calabretto, Giulia |
| dc.contributor.author | Fürstenau, Moritz |
| dc.contributor.author | Rogers, Kerry |
| dc.contributor.author | Baliakas, Panagiotis |
| dc.contributor.author | Abrisqueta, Pau |
| dc.date.accessioned | 2025-10-03T08:36:44Z |
| dc.date.available | 2025-10-03T08:36:44Z |
| dc.date.issued | 2025-07-22 |
| dc.identifier.citation | Roncaglia E, Gaffo E, Calabretto G, Fürstenau M, Rogers KA, Baliakas P, et al. Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study. J Hematol Oncol. 2025 Jul 22;18:74. |
| dc.identifier.issn | 1756-8722 |
| dc.identifier.uri | http://hdl.handle.net/11351/13765 |
| dc.description | Circular RNA |
| dc.description.abstract | In Chronic Lymphocytic Leukemia (CLL), t(14;19)(q32;q13), leading to the overexpression of BCL3, is found in ∼1% of cases and is associated with an aggressive disease. In this study, leveraging a large CLL patient cohort collected thanks to an international collaboration, we investigate for the first time the circular transcriptome (circRNAome) associated with the rare t(14;19), in comparison with CLL without t(14;19) and B cells of age-matched healthy donors. We described the circRNAs commonly dysregulated in CLL, including circCSNK1G3 and circEXOC6B(3–5), which were depleted, and circZNF609 and circLPAR3, which were overexpressed in malignant cells. Of importance, we disclosed the circRNA signature of CLL with t(14;19), formed by circRNAs with expression significantly altered specifically in link with this lesion, ectopically expressed like circCDK14(3–4), circCORO1C, circCLEC2D, and circEMB, or downregulated like circCEP70(3–6). Several of these molecules were previously shown to be dysregulated or play a role in cancer, whereas most of the signature circRNAs deserve further investigation. CLL patients with high circCORO1C and circCLEC2D expression had significantly worse clinical outcomes, with shorter time to first treatment and overall survival. This study disclosed new molecular features of the aggressive CLL subtype with t(14;19). |
| dc.language.iso | eng |
| dc.publisher | BMC |
| dc.relation.ispartofseries | Journal of Hematology & Oncology;18 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Leucèmia limfocítica crònica - Aspectes genètics |
| dc.subject | RNA |
| dc.subject | Cromosomes humans |
| dc.subject | Factors de transcripció |
| dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
| dc.subject.mesh | /genetics |
| dc.subject.mesh | RNA |
| dc.subject.mesh | Chromosomes, Human, Pair 14 |
| dc.subject.mesh | Transcription Factors |
| dc.title | Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1186/s13045-025-01725-y |
| dc.subject.decs | leucemia linfocítica crónica de células B |
| dc.subject.decs | /genética |
| dc.subject.decs | ARN |
| dc.subject.decs | cromosomas humanos par 14 |
| dc.subject.decs | factores de transcripción |
| dc.relation.publishversion | https://doi.org/10.1186/s13045-025-01725-y |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Roncaglia E] Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy. Department of Biology, University of Padua, Padova, Italy. [Gaffo E] Department of Molecular Medicine, University of Padua, Padova, Italy. [Calabretto G] Hematology Unit, Department of Medicine, University of Padua, Padova, Italy. [Fürstenau M] Department I of Internal Medicine, University of Cologne, Cologne, Germany. [Rogers KA] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. [Baliakas P] Department of Immunology, Genetics and Pathology & Clinical Genomics Uppsala, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. [Abrisqueta P] Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 40691637 |
| dc.identifier.wos | 001532814500001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |